



MELANOMA RESEARCH AND THERAPY IN NEW ZEALAND: RAISING THE BAR THROUGH COLLABORATIVE ACTION

<p style="text-align: center;">QRW Programme Melanoma Research and Therapy in New Zealand: Raising the Bar through Collaborative Action Saturday 9 September 2017 Rydgas Hotel, Queenstown, New Zealand</p>
--

Saturday 9 September		
Time	Details	Location
	Session 1	
8.00am - 8.30am	Opening Professor Peter Shepherd Queenstown Research Week Challenge to participants Paul O'Neil Melanoma New Zealand Scene setting and meeting aim Dr Rosalie Stephens Melanoma New Zealand Professor Mike Eccles <i>sponsored by Bio-Strategy</i> Melanoma Network of New Zealand (MelNet)	Clancys Room
8.30am - 9.15am	Professor David Whiteman (M1) <i>sponsored by MelNet and Thermo Fisher Scientific</i> Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Australia <i>Melanoma epidemiology and risk assessment</i>	Clancys Room
9.15am - 10.00am	Professor Mel Ziman (M2) <i>sponsored by Maurice and Phyllis Paykel Trust and Bio-Rad Laboratories Pty Ltd</i> School of Medical and Health Sciences, Edith Cowan University, Perth, Australia <i>Blood based biomarkers for diagnosis, prognosis and monitoring of patients with melanoma</i>	Clancys Room
10.00am - 10.30am	Morning tea	Level 5 Foyer
	Session 2	
10.30am - 11.15am	Professor Mark Shackleton (M3) <i>sponsored by Merck Sharp Dohme New Zealand and Thermo Fisher Scientific</i> Alfred Health and Monash University, Melbourne, Australia <i>Melanoma heterogeneity – the elephant in the room</i>	Clancys Room
11.15am - 12.00pm	Dr Michelle Wilson (M4) Auckland City Hospital, Auckland, New Zealand Paul O'Neil (M4) , <i>sponsored by Merck Sharp Dohme New</i>	Clancys Room

	<p><i>Zealand</i></p> <p>Melanoma New Zealand</p> <p><i>Understanding and facilitating clinical research in melanoma</i></p>	
--	--	--

12.00pm - 1.00pm	Lunch and concurrent poster session	Level 5 Foyer
12.00pm – 1.00pm	Poster Session	Clancys Room

	Session 3	
1.00pm - 3.00pm	<p>Dr Mary Jane Sneyd (M5) <i>sponsored by MelNet</i> HACEU, University of Otago, Dunedin, New Zealand <i>An online melanoma risk prediction tool specifically for New Zealanders</i></p> <p>Professor Mike Eccles (M6) <i>sponsored by Bio-Strategy</i> Department of Pathology, University of Otago, Dunedin, New Zealand <i>Can research involving NZ melanoma patient participation and extensive networking by researchers help reduce the melanoma burden in NZ?</i></p> <p>Professor Rod Dunbar (M7) <i>sponsored by Thermo Fisher Scientific</i> Maurice Wilkins Centre & School of Biological Sciences, University of Auckland, Auckland, New Zealand <i>Making immune therapy work for more melanoma patients</i></p> <p>Professor Cristin Print (M8) <i>sponsored by Bio-Strategy</i> Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand <i>The promise and challenge of melanoma genomics</i></p> <p>Professor Bruce Baguley (M9) Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand <i>Growing melanoma cells from surgical samples: what have we learnt?</i></p> <p>Professor Peter Shepherd (M10) <i>sponsored by Bio-Rad Laboratories Pty Ltd</i> Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand <i>Lessons for melanoma therapy gained from studies in the NZM melanoma cell line panel</i></p> <p>Dr Jacqui Gardner (M11) Department of Pathology, Canterbury District Health Board, Christchurch, New Zealand <i>Working towards a molecular classification of melanoma</i></p>	Clancys Room
3.00pm - 3.30pm	Afternoon tea	Level 5 Foyer

	Session 4	
3.30pm - 4.15pm	<p>Mr Richard Martin (M12) Melanoma Unit and Waitemata District Health Board, Auckland, New Zealand <i>What role does the surgeon have in contemporary melanoma management and research?</i></p> <p>Dr Rosalie Stephens (M13) Auckland City Hospital, Auckland, New Zealand <i>Strategies to improve access to melanoma clinical research in New Zealand</i></p> <p>Dr Sanjeev Deva (M14) Auckland City Hospital, Auckland, New Zealand <i>Establishment of an early phase clinical trials unit</i></p>	Clancys Room
4.15pm - 5.00pm	<p>Draft consensus statement and meeting recommendations Dr Cristin Print <i>sponsored by Bio-Strategy</i></p>	Clancys Room
5.00pm - 6.00pm	Social hour	Reds Bar

Poster Session Summary 12pm – 1pm Clancys Room

No.	Title	Presenter	Institutions
M15	<i>Genomic variations of the mevalonate pathway and roles of bisphosphonate in melanoma</i>	Khanh Tran	Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand
M16	<i>Development of single-cell methodologies to interrogate DNA methylation patterns at a whole genome scale</i>	Dr. Aniruddha Chatterjee	University of Otago, Dunedin, New Zealand
M17	<i>Stratification of melanoma patients according to PD-L1 expression, CpG methylation and presence of tumour-infiltrating lymphocytes</i>	Dr Euan Rodger	University of Otago, Dunedin, New Zealand
M18	<i>Epigenetic drivers of melanoma metastasis identified by genome-wide reduced-representation bisulphite sequencing (RRBS) analysis</i>	Professor Mike Eccles	University of Otago, Dunedin, New Zealand
M19	<i>Characterizing the therapeutic potential of crizotinib in cutaneous malignant melanoma</i>	Dr Elisha Hayden	Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand